- Home
- Publications
- Publication Search
- Publication Details
Title
Harnessing NK Cells for Cancer Treatment
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-12-06
DOI
10.3389/fimmu.2019.02836
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy
- (2019) Elisa Zaghi et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
- (2019) Simona Sivori et al. Cellular & Molecular Immunology
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- NK cells to cure cancer
- (2019) Clara Di Vito et al. SEMINARS IN IMMUNOLOGY
- Dose-ranging and cohort-expansion study of monalizumab(IPH2201) in advanced gynecologic malignancies:A trial of the Canadian Cancer Trials Group (CCTG):IND221
- (2019) Anna V Tinker et al. CLINICAL CANCER RESEARCH
- PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
- (2019) Silvia Pesce et al. Frontiers in Immunology
- Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
- (2019) Kyle B. Lupo et al. Cancers
- Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
- (2019) Ziqing Chen et al. Cancers
- The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
- (2019) Haoyu Sun et al. Frontiers in Immunology
- NK Cell-Based Immunotherapy for Hematological Malignancies
- (2019) Simona Sivori et al. Journal of Clinical Medicine
- The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation
- (2018) Alessandra Roberto et al. HAEMATOLOGICA
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
- (2018) Norbert Vey et al. Oncotarget
- The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation
- (2018) Alessandra Roberto et al. HAEMATOLOGICA
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies
- (2018) Sandro Matosevic Journal of Immunology Research
- Not All Immune Checkpoints Are Created Equal
- (2018) Annika De Sousa Linhares et al. Frontiers in Immunology
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression
- (2018) Silvia Pesce et al. Frontiers in Immunology
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
- (2017) Michal Šmahel INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
- (2017) Laura Chiossone et al. SEMINARS IN IMMUNOLOGY
- NK cell-based immunotherapy for cancer
- (2017) Fang Fang et al. SEMINARS IN IMMUNOLOGY
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
- (2017) Veronika Kremer et al. Journal for ImmunoTherapy of Cancer
- Exploitation of natural killer cells for the treatment of acute leukemia
- (2016) Rupert Handgretinger et al. BLOOD
- Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
- (2016) A. Curti et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
- (2016) Emily M. McWilliams et al. OncoImmunology
- The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
- (2015) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction
- (2015) Claudia A Nold-Petry et al. NATURE IMMUNOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors
- (2015) HIDEO KOMITA et al. ONCOLOGY REPORTS
- B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
- (2015) Silvia Pesce et al. OncoImmunology
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment
- (2014) Alessandro Isidori et al. Expert Review of Hematology
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- TLR/NCR/KIR: Which One to Use and When?
- (2014) Simona Sivori et al. Frontiers in Immunology
- Reversal of natural killer cell exhaustion by TIM-3 blockade
- (2014) Anne Gallois et al. OncoImmunology
- KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts
- (2013) E. Marcenaro et al. BLOOD
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations
- (2013) Haoyu Sun et al. CYTOKINE
- Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells
- (2013) Franco Locatelli et al. Frontiers in Immunology
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation
- (2011) Emanuela Marcenaro et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Melanoma drug wins US approval
- (2011) Heidi Ledford NATURE
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
- (2010) N. K. Bjorkstrom et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
- (2010) L. Moretta et al. BLOOD
- T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B
- (2010) Ying Ju et al. JOURNAL OF HEPATOLOGY
- Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction
- (2009) E. Marcenaro et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity
- (2008) D. Pende et al. BLOOD
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now